GUARANTYGuaranty • October 31st, 1995 • Roche Holdings Inc • Delaware
Call/Put: CallOtc Contract Note • February 28th, 2002 • Roche Holdings Inc
Payment Instructions: swissfirst Bank AG. for account Nr. 3671_0 -------------------------------------------------------------------------------- To be transmitted by telefax to swissfirst Bank AG: Telefax Number +4441-1-204 81 81 Acknowledged by: Roche Holdings, Inc.
AMENDMENT NO. 1 TO THE NON-DISCLOSURE AGREEMENT by and betweenNon-Disclosure Agreement • December 9th, 2024 • Roche Holdings Inc
This amendment no. 1 to the Non-Disclosure Agreement effective as of 9 March 2021 (“Amendment No. 1”) is effective as of November 19, 2021(the “Amendment No. 1 Effective Date”) by and between
MUTUAL NON-DISCLOSURE AGREEMENTMutual Non-Disclosure Agreement • March 7th, 2019 • Roche Holdings Inc • Delaware
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Therapeutics, Inc., a Delaware corporation, having an address at 3737 Market Street, Suite 1300, Philadelphia, PA (“Spark”), and Roche Holdings Inc, a Delaware company having an address at 1 DNA Way, South San Francisco, CA 94080 (“Company”). For purposes of this Agreement, references to each of Spark and Company, and corresponding references to disclosing party and receiving party herein, shall include the respective subsidiaries and other entities controlled, directly or indirectly by Spark or Company, as the case may be; provided, however, with respect to Company, the foregoing provision shall exclude Chugai Pharmaceutical Co., Ltd, 1-1 Nihonbashi-Muromachi 2-chome, Chuo-ku, Tokyo, 103-8324 (“Chugai”) unless the Company opts for such inclusion of Chugai and their respective subsidiaries by giving written notice
Amendment NO.1 to Agreement and Plan of MergerAgreement and Plan of Merger • July 8th, 2019 • Roche Holdings Inc
This Amendment NO.1 to Agreement and Plan of Merger (this “Amendment”) is entered into as of July 5, 2019 by and among Roche Holdings, Inc., a Delaware corporation (“Parent”), 022019 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Spark Therapeutics, Inc., a Delaware corporation (the “Company” and, together with Parent and Merger Sub, the “Parties”).
AMENDMENT NO. 2 TO THE NON-DISCLOSURE AGREEMENTNon-Disclosure Agreement • December 9th, 2024 • Roche Holdings Inc
This amendment No. 2 to the Non-Disclosure Agreement (the “Amendment No. 2”) is made and entered into effective as of 10 March, 2023 (the “Amendment No. 2 Effective Date”) by and between
CONFIDENTIALITY AGREEMENTConfidentiality Agreement • March 25th, 2021 • Roche Holdings Inc • Delaware
This Confidentiality Agreement (“Agreement”) is entered into as of February 19, 2020 (“Effective Date”) by and between Roche Holdings, Inc., a Delaware corporation having its principal address at 1 DNA Way, South San Francisco, CA 94080 (“Recipient”), and GenMark Diagnostics, Inc., a Delaware corporation having its principal place of business at 5964 La Place Court, Carlsbad, California 92008 (together with its wholly owned subsidiaries, “Discloser”). The parties wish to protect and preserve the confidential and/or proprietary nature of information and materials that may be disclosed or made available to each other in connection with certain discussions, negotiations or dealings between the parties relating to Discloser’s exploration of certain business development and/or strategic initiatives (the “Purpose”). For purposes of this Agreement, references to each of Recipient and Discloser herein shall include the respective subsidiaries, affiliates and other entities controlled, directly
Confidentiality Agreement IGNYTA, INC.Confidentiality Agreement • January 10th, 2018 • Roche Holdings Inc • California
NON-DISCLOSURE AGREEMENTNon-Disclosure Agreement • December 9th, 2024 • Roche Holdings Inc
This Non-Disclosure Agreement (“Agreement”), effective March 9, 2021 (“Effective Date”), is by and between F. Hoffmann-La Roche Ltd, with offices at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche”) and Poseida Therapeutics, Inc., with offices at 9390 Towne Centre Dr #200, San Diego, CA 92121 (“Company”).
CONFORMED COPY -------------- AMENDED AND RESTATED GOVERNANCE AGREEMENT Agreement dated as of October 25, 1995 between Roche Holdings, Inc., a Delaware corporation ("Roche"), and Genentech, Inc., a Delaware corporation (the "Company"). WHEREAS, Roche,...Governance Agreement • October 31st, 1995 • Roche Holdings Inc • Delaware
